These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9174826

  • 21. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
    Venesmaa P.
    Obstet Gynecol; 1994 Jul; 84(1):8-11. PubMed ID: 8008329
    [Abstract] [Full Text] [Related]

  • 22. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 23. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care.
    Acta Oncol; 2001 Oct; 40(2-3):340-60. PubMed ID: 11441940
    [Abstract] [Full Text] [Related]

  • 24. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
    Culine S, Theodore C, Farhat F, Bekradda M, Terrier-Lacombe MJ, Droz JP.
    J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
    [Abstract] [Full Text] [Related]

  • 25. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
    Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I.
    Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
    [Abstract] [Full Text] [Related]

  • 26. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F, Viens P, Delpero JR, Bardou VJ, Faucher C, Houvenaeghel G, Maraninchi D.
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [Abstract] [Full Text] [Related]

  • 27. Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
    Menczer J, Ben-Baruch G, Rizel S, Brenner H.
    Eur J Gynaecol Oncol; 1995 Jul; 16(1):12-7. PubMed ID: 7744111
    [Abstract] [Full Text] [Related]

  • 28. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study.
    Zang RY, Li ZT, Zhang ZY, Cai SM.
    Int J Gynecol Cancer; 2003 Jul; 13(4):419-27. PubMed ID: 12911717
    [Abstract] [Full Text] [Related]

  • 29. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Pérez-Milán F, Ortiz-Quintana L.
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [Abstract] [Full Text] [Related]

  • 30. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [Abstract] [Full Text] [Related]

  • 31. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer.
    Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT.
    Gynecol Oncol; 1991 Aug; 42(2):146-50. PubMed ID: 1894174
    [Abstract] [Full Text] [Related]

  • 32. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A, Ditto A, Giorda G, Gadducci A, Greggi S, Daniele A, Fuso L, Panuccio E, Scaffa C, Raspagliesi F, Sismondi P, Biglia N.
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S.
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [Abstract] [Full Text] [Related]

  • 39. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J, Yang W, Wu X.
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [Abstract] [Full Text] [Related]

  • 40. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
    Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Toole RV, Terada KY, Franklin EW, Herrer GW, Goldberg DA, Hannigan EV.
    Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.